Literature DB >> 11099585

The changing demographics of neonatal extracorporeal membrane oxygenation patients reported to the Extracorporeal Life Support Organization (ELSO) Registry.

B J Roy1, P Rycus, S A Conrad, R H Clark.   

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is an important treatment tool in the management of near-term and term neonates with severe hypoxemic respiratory failure. To better understand how health care for patients treated with ECMO has changed, we studied the demographic and treatment data reported to the Extracorporeal Life Support Organization (ELSO) registry from January 1, 1988, through January 1, 1998.
METHODS: We used data stored in the ELSO registry and evaluated the changes in demographics, use of alternate therapies before ECMO, severity of illness, duration of ECMO therapy, and mortality over a 10-year period. All data on neonates reported between January 1, 1988, and January 1, 1998 were used. Verification checks were performed on all fields to eliminate nonsense outliers. We separated the neonates into 2 groups-those with and those without a congenital diaphragmatic hernia (CDH). All analyses were performed on the total group and each subgroup separately. Changes in continuous data were analyzed by year using analysis of variance. Year differences in categorical data were evaluated with chi(2) analysis. We also used the linear trend test and the Cochran-Armitage trend test to evaluate time-related changes.
RESULTS: We reviewed 12 175 neonates. Over the decade, there were no changes in mean gestational age, gender, age at which ECMO was started, pH, or PaCO(2) just before ECMO. The proportion of neonates with CDH increased from 18% to 26%, while the proportion with respiratory distress syndrome decreased from 15% to 4%. Other diagnostic categories remained constant. The use of surfactant, high-frequency ventilation, and inhaled nitric oxide increased from 0% in 1988 to 36%, 46%, and 24%, respectively, in 1997. The mean peak pressure being used just before ECMO decreased (47 +/- 10 in 1988 to 39 +/- 12 in 1997), and the mean PaO(2)/FIO(2) ratio increased (38 +/- 23 in 1988 to 48 +/- 36 in 1997). The primary mode of ECMO remains venoarterial; however, the use of venovenous ECMO increased from 1% to 32% over the decade. Duration of ECMO treatment increased overall, and this trend was seen for patients with and without CDH (124 +/- 67 to 141 +/- 104 hours for the non-CDH group, 161 +/- 99 to 238 +/- 141 hours for the CDH group). The number of centers reporting neonatal data to the ELSO registry increased from 52 in 1988 to a peak of 100 in 1993. In 1997, 96 centers reported data to ELSO. The average number of neonatal patients reported from each site decreased from a peak of 18 in 1991 to 9 in 1997. Mortality increased from 18% to 22%; however, when corrected for the relative increase in neonates with CDH, this trend disappeared. Diagnoses-specific mortality rates remained constant. The occurrence of intracranial hemorrhage and/or infarct also stayed constant at 16%.
CONCLUSIONS: The population of neonates treated with ECMO in 1997 was very different from patients treated in the 1980s and early 1990s. They were exposed to an ever-expanding group of new therapies, appeared to be healthier based on indices of gas exchange, and were cared for at centers that reported fewer cases per year.

Entities:  

Mesh:

Year:  2000        PMID: 11099585     DOI: 10.1542/peds.106.6.1334

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

Review 1.  Alveolar capillary dysplasia.

Authors:  Naomi B Bishop; Pawel Stankiewicz; Robin H Steinhorn
Journal:  Am J Respir Crit Care Med       Date:  2011-03-11       Impact factor: 21.405

2.  Neonatal respiratory extracorporeal membrane oxygenation and primary diagnosis: trends between two decades.

Authors:  Jotishna Sharma; Ashley Sherman; Anisha Rimal; Barb Haney; Julie Weiner; Eugenia Pallotto
Journal:  J Perinatol       Date:  2019-11-07       Impact factor: 2.521

Review 3.  Extracorporeal life support: experience with 2,000 patients.

Authors:  Brian W Gray; Jonathan W Haft; Jennifer C Hirsch; Gail M Annich; Ronald B Hirschl; Robert H Bartlett
Journal:  ASAIO J       Date:  2015 Jan-Feb       Impact factor: 2.872

4.  Is age at initiation of extracorporeal life support associated with mortality and intraventricular hemorrhage in neonates with respiratory failure?

Authors:  K M Smith; D M McMullan; S L Bratton; P Rycus; J P Kinsella; T V Brogan
Journal:  J Perinatol       Date:  2014-03-06       Impact factor: 2.521

5.  A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center.

Authors:  T Schaible; D Hermle; F Loersch; S Demirakca; K Reinshagen; V Varnholt
Journal:  Intensive Care Med       Date:  2010-04-28       Impact factor: 17.440

6.  Morbidity and mortality in late preterm infants with severe hypoxic respiratory failure on extra-corporeal membrane oxygenation.

Authors:  Ashwin Ramachandrappa; Eli S Rosenberg; Scott Wagoner; Lucky Jain
Journal:  J Pediatr       Date:  2011-04-02       Impact factor: 4.406

Review 7.  Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates.

Authors:  Marcia L Buck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Innovative neonatal ventilation and meconium aspiration syndrome.

Authors:  Vinod K Bhutani; Ranjit Chima; Emidio M Sivieri
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

Review 9.  High frequency oscillatory ventilation versus conventional ventilation for infants with severe pulmonary dysfunction born at or near term.

Authors:  David J Henderson-Smart; Antonio G De Paoli; Reese H Clark; Tushar Bhuta
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Expanded application of extracorporeal membrane oxygenation in a pediatric surgery practice.

Authors:  Max Raymond Langham; David William Kays; Elizabeth Ann Beierle; Mike K Chen; Karla Stringfellow; James Lewis Talbert
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.